Available Technologies
# of Displayed Technologies: 4 / 4
Applied Category Filter (Click To Remove): Therapeutics
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Bhatti, Hamid
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Bhatti, Hamid
Novel method for attenuating live vaccine candidates for non-segmented negative-sense RNA viruses
TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease
Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; He, Chuan; Lu, Mijia; Niewiesk, Stefan; Peeples, Mark; Xue, Miaoge; Zhang, Zijie; Zhao, Boxuan
- Licensing Officer: Willson, Christopher
An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-target activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases that are lacking effective therapeutic treatments. The main bottleneck in developing effective treatment is the ability to effectively edit gene while controlling for the myriad of off-target effects that come with targeting the genome. Duchenne Muscular D…
- College: College of Medicine (COM)
- Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
- Licensing Officer: Schworer, Adam
